Peptide Encyclopedia / Vesugen
EncyclopediaVesugen is a short synthetic peptide, commonly cited as the tripeptide Lys-Glu-Asp, from the Khavinson bioregulator family and marketed toward blood-vessel tissue. Its proposed role in vascular gene expression stays unproven, resting on Russian preclinical work that independent Western human studies have not replicated. It is not FDA-approved and trades as a gray-market research chemical in the US. Below you'll find reported dosing, safety, and legal status. Educational only, not medical advice.
| Category | Longevity / Anti-aging |
| Regulatory status | Not FDA-approved; research chemical / gray-market in the US. |
A short synthetic peptide (commonly cited as the tripeptide Lys-Glu-Asp) from the Khavinson bioregulator family, marketed as a vascular/blood-vessel-targeted agent. Proposed (unproven) mechanism is tissue-specific modulation of gene expression supporting vascular endothelial function.
uncertain / limited human pharmacokinetic data; presumed rapid clearance for a tripeptide but no rigorous human PK exists.
Not FDA-approved; research chemical / gray-market in the US. Not an FDA-approved drug; sold within Russia in the bioregulator/supplement context only.
Human safety data are minimal and largely Russian-sourced. Rapid clearance suggests low acute risk but is not a substitute for controlled safety data. Gray-market purity/identity unverified.
Weak/limited evidence base: predominantly Russian (Khavinson group) preclinical work, with essentially no independent Western human replication.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. Vesugen may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
